Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Oct;7(10):1060-5.
doi: 10.4161/hv.7.10.16480. Epub 2011 Oct 1.

Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years

Robert Arnou  1 , Anne Fiquet, Stéphane Thomas, Christine Sadorge
Affiliations
Clinical Trial

Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years

Robert Arnou et al. Hum Vaccin. 2011 Oct.

Abstract

Background: Age is a major risk factor for herpes zoster (HZ) and its potential long-term complication post-herpetic neuralgia (PHN). Due to the significant burden of HZ and PHN on patients' quality of life, it is vital that effective and well-tolerated vaccines are available to prevent HZ in older adults. ZOSTAVAX(®) vaccine was developed to prevent HZ and PHN in individuals ≥50 years (y) of age, and its clinical efficacy and safety have been demonstrated.

Aims and methods: This phase 4, open-label, multicenter study was undertaken to assess the immunogenicity and safety of a single dose of ZOSTAVAX (refrigerator-stable formulation) given within 6 mo of its expiry date in individuals ≥50 y of age. The geometric mean fold rise (GMFR) from pre-vaccination to 4 weeks post-vaccination in varicella zoster virus (VZV) antibody titers was calculated. An acceptable antibody response was defined as a lower 95% confidence interval (CI) of GMFR > 1.4. Solicited and unsolicited injection-site reactions and systemic adverse events were recorded.

Results: The GMFR in VZV antibody titers was 3.1 (95% CI: 2.6, 3.8), satisfying the criterion for an acceptable VZV antibody response to ZOSTAVAX (minimum requirement: 1.4 GMFR). An acceptable rise in VZV antibody titers was observed in individuals of 50-59 y of age (GMFR 3.9; 95% CI: 2.9, 5.1) and in those ≥60 y of age (GMFR 2.5; 95% CI: 1.9, 3.2). ZOSTAVAX was well tolerated; no serious adverse events were reported.

Conclusion: ZOSTAVAX elicits an acceptable immune response in immunocompetent individuals ≥50 y of age when stored as directed and administered during the 6 mo prior to expiration.

Trial registration: ClinicalTrials.gov NCT00681031.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reverse cumulative distribution of varicella zoster virus (VZV) antibody titers (log scale) before vaccination and 28–35 d following vaccination with ZOSTAVAX at minimum-release specification approaching expiry potency (per-protocol set; n = 92). BS1, blood sample 1 (before vaccination); BS2, blood sample 2 (28–35 d following vaccination).
See this image and copyright information in PMC

References

    1. Arvin AM. Varicella-zoster virus. In: DM Knipe, PM Howley., editors. Fields Virology. 4th. Vol. 2. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2731–2768.
    1. Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA. 1995;92:10980–10984. doi: 10.1073/pnas.92.24.10980. - DOI - PMC - PubMed
    1. Gauthier A, Breuer J, Carrington D, Martini M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38–47. doi: 10.1017/S0950268808000678. - DOI - PubMed
    1. Gnann JW, Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340–346. doi: 10.1056/NEJMcp013211. - DOI - PubMed
    1. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481–1486. doi: 10.1086/320169. - DOI - PubMed

Publication types

Associated data